NAPWA

It appears that the antiretroviralA medication or other substance which is active against retroviruses such as HIV. NRTIA type of anti-HIV drug that works by inhibiting a stage of the HIV life cycle called reverse transcription. Non-nucleosides work in a similar way, but are chemically different. tenofovir (found in Viread, Truvada and Atripla) may also have a calming effect on the immune system and provide protection against infections other than HIV. Laboratory tests have found that tenofovir offered two types of protection. First, it suppressed the production of inflammatory messengers, such as Interleukin-8 (IL-8). read more »

From 1 January 2010 and for the cost of a single PBS[Pharmaceutical Benefits Scheme[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs.] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. script, Australians will be able to access Atripla, the first HIV medication to combine three treatments in a single once-a-day tablet. read more »

In September 2006, the International Association of Physicians in AIDS Care will mark a decade of highly active antiretroviralA medication or other substance which is active against retroviruses such as HIV. therapy. Has it really been 10 years since the so-called Protease Moment? KIRSTY MACHON reports on where we have come from – and where to from here. read more »

The 13th annual Conference on Retroviruses and Opportunistic Infections (CROI) took place in Denver, Colorado, from February 5 to 8. The major breaking news from this conference was the premature cancellation of the SMART study, but as usual, this important conference produced a great deal more than a single story. read more »

HIV-related news in brief from the April 2006 edition of Positive Living. read more »

Nucleoside analoguesA type of anti-HIV drug that works by inhibiting a stage of the HIV life cycle called reverse transcription. Non-nucleosides work in a similar way, but are chemically different. are the backbone of successful anti-HIV treatments. This article examines some of the issues involved in selecting the best nucleoside backbone. read more »

Kivexa, a new single-pill combination of the antiviralA medication or substance which is active against one or more virusesA small infective organism which is incapable of reproducing outside a host cell.. May include anti-HIV drugs, but these are more accurately termed antiretroviralsA medication or other substance which is active against retroviruses such as HIV.. drugs abacavir (Ziagen) and lamivudine (3TC) became available for S100 prescription from 1 December. read more »

The HIV drug manufacturers Gilead Sciences, Bristol-Myers Squibb (BMS) and Merck have announced a joint venture to develop a single-pill, once-a-day HIV treatment. read more »

With major medical conferences in the United States and Scotland, November was a busy month for HIV medicine. PAUL KIDD reviews some key findings. read more »

Three of the biggest anti-HIV drug manufacturers have announced that they have commenced “early discussions” on developing the first licensed fixed-dose combination therapyHighly Active AntiRetroviralA medication or other substance which is active against retroviruses such as HIV. Therapy ??? aggressive treatment of HIV infection using several different drugs together. incorporating drugs from more than one manufacturer. read more »